Society. We suggest, however, that this first report of the use of a marker gas during manual aspiration of spontaneous pneumothorax has provided information about the likely short term outcome that cannot reliably be determined on the basis of the postaspiration chest radiograph alone and that this information may guide the clinician as to whether or not tube drainage is likely to be required. Results-There was a highly significant decrease (median Alutard SQ v median placebo (95% confidence interval for difference between medians)) in total symptom scores (p=0-001) in the Alutard SQ treated group (360 v 928 (238 to 825)). Significant differences were also found in total drug use (p=0-002, 129 v 627 (178 to 574)). Visual analogue symptom scores were also reduced in the active group (p=002, 2-2 v 5-5 (-4-8 to-0-5)). The postseasonal assessment, by either the doctor or the patients, showed a large improvement (p<0-001) in favour of Alutard SQ. Provocation tests showed a greater than 10-fold reduction for the active group in immediate conjunctival allergen sensitivity (p= 0.001), a 40% decrease in early phase response (p=002), and a 57% decrease in the late phase (p=0-001) cutaneous response after intradermal allergen. A total of 523 active injections were given.
Objective-To evaluate the efficacy and safety of immunotherapy (hyposensitisation) in patients with severe summer hay fever.
Design-A randomised, double blind, placebo controlled study of a biologically standardised depot grass pollen extract.
Setting-Allergy clinic, Royal Brompton and National Heart Hospital, London.
Patients-40 adults (mean age 35 years) with a history of severe grass pollen allergy uncontrolled by standard antiallergic drugs. Patients with perennial asthma were specifically excluded.
Intervention-Patients were randomised to receive either an active preparation (Alutard SQ, a grass pollen (Phleum pratense) extract) or placebo at a rate of two subcutaneous injections a week in increasing doses until a maintenance dose was reached. This maintenance dose was given once a month.
Main outcome measures-Clinical efficacy was evaluated by symptom and drug diary cards, visual analogue scores during the grass pollen season, and a postseasonal assessment by the patients and a doctor. Conjunctival and skin sensitivity to local allergen provocation was measured before and after eight months of treatment.
Results-There was a highly significant decrease (median Alutard SQ v median placebo (95% confidence interval for difference between medians)) in total symptom scores (p=0-001) in the Alutard SQ treated group (360 v 928 (238 to 825)). Significant differences were also found in total drug use (p=0-002, 129 v 627 (178 to 574)). Visual analogue symptom scores were also reduced in the active group (p=002, 2-2 v 5-5 (-4-8 to-0-5)). The postseasonal assessment, by either the doctor or the patients, showed a large improvement (p<0-001) in favour of Alutard SQ. Provocation tests showed a greater than 10-fold reduction for the active group in immediate conjunctival allergen sensitivity (p= 0.001), a 40% decrease in early phase response (p=002), and a 57% decrease in the late phase (p=0-001) cutaneous response after intradermal allergen. A total of 523 active injections were given. There was one systemic reaction at 10 minutes after injection, which was rapidly reversed with intramuscular adrenaline. There was one mild delayed urticarial reaction at 21/2 hours.
Conclusion-Immunotherapy is effective in patients with severe summer hay fever, but immediate anaphylactic reactions limit its use to specialised
Introduction
Over the past 30 years there has been a substantial increase in the prevalence of summer hay fever in the United Kingdom. 1 At the same time there have also been considerable improvements in treatment, particularly with the introduction of non-sedating selective histamine HI antagonists2 and local nasal corticosteroids. Nevertheless, a minority of people with hay fever have extreme hypersensitivity to grass pollen and respond poorly to standard antiallergic drugs. In these people immunotherapy (hyposensitisation) would be the treatment of choice in many countries throughout the world, including the United States, Scandinavia, and the continent of Europe.34
In the United Kingdom allergen injection immunotherapy for treating disease mediated by IgE, including summer hay fever, has been largely discontinued on the recommendations of the Committee on Safety of Medicines in October 1986.5 The committee's report questioned the efficacy of immunotherapy and expressed concern about the number of deaths from severe bronchospasm and anaphylaxis. The committee recommended that injections should be given only where facilities for full cardiorespiratory resuscitation were immediately available, and that patients be kept under medical observation for at least two hours.
Generally, the committee's ruling was welcomed because it highlighted the potential dangers of immunotherapy, particularly in asthmatic patients. Nevertheless, the two hour waiting period has made this treatment impracticable for both patients and doctors.
For immunotherapy to retain a place in the treatment of summer hay fever we thought that a double blind, placebo controlled study in highly sensitive patients who were inadequately controlled by standard treatment was necessary in the United Kingdom. Previous studies have been described,6-but we are unaware of any double blind, placebo controlled studies using a biologically standardised extract. Such a study would re-evaluate the important issues of side effects and their timing along with efficacy. We chose the Alutard SQ vaccine as this is a biologically standardised depot preparation with a reported low incidence of systemic side effects and high efficacy.9'" BMJ VOLUME 302 A ("extremely 9 9 hypersensitive") B ("very hypersensitive") 12 10 * Severity score A = skin prick test >16mm; positive conjunctival provocation test at <300 biological units/ml; history of symptoms for >10 weeks associated with asthma and previous oral or injected corticosteroids, or both. Severity score B=patients with moderate to severe hay fever who did not fulfil all of above criteria.
STUDY DESIGN
The study was performed with the approval of the Royal Brompton and National Heart Hospital ethics committee and had the patients' written informed consent. The patients were divided into two grades A and B (A=extremely hypersensitive and B=very hypersensitive) according to the severity of their symptoms (expressed as their severity score) and their skin and conjunctival response to allergen (table I) . Patients in each grade were then randomised separately to active and placebo groups to ensure an even distribution of disease severity. Random allocation was performed by using computer generated random numbers. The groups were well matched for age and duration of disease. The coordinator, who was "blinded," was in charge of patient supervision and the adjustment ofrescue treatment according to symptoms. She also performed objective (skin and conjunctival) and subjective tests before and after the pollen season. The immunotherapy injections were given by two doctors (operators) who had experience in this treatment and knew whether the patients were receiving either active or placebo preparations. Thus any reactions were. seen and reported by the doctor who gave the injections and not by the blinded coordinator.
IMMUNOTHERAPY PROTOCOL
The active (Alutard SQ) and placebo treatment packs were identical. The placebo was 0 9% sodium chloride. During the induction phase this was randomly "spiked" with 0 01 mg/ml of histamine acid phosphate (in phosphate buffered saline, pH 7 4). This concentration had previously been shown to produce local erythema and itching. A single batch of Alutard SQ (Allergologisk Laboratorium, Denmark) a partially purified and standardised extract of Phleum pratense was used throughout the study. 13 This extract is aluminium adsorbed for slow release.9'-Subcutaneous injections were started in April 1989 at a rate of two injections a week. The schedule of doses is shown in table II. Adjustments in the schedule were made on an 
ASSESSMENTS
All patients recorded daily symptom scores and drug requirements from April to October. The severity of individual symptoms was assessed on a scale of 0-3 for chest (breathlessness, coughing, wheezing, and tightness), nose (sneezing, blocking, and running), eyes (itching, redness, streaming, and swelling), and mouth and throat symptoms (itching and dryness). Antiallergic drugs in the form of sodium cromoglycate eye drops and nasal spray were allowed freely, along with the short acting antihistamine acrivastine (8 mg every 6-8 hours as required) and the inhaled 6 agonist, salbutamol. Nasal corticosteroids were not allowed. 
Results
A total of 37 (93%) patients completed the study. The three patients who dropped out were from the placebo group. In two this was due to family problems and in the third delayed systemic reactions (shortness of breath) several hours after placebo injections. These withdrawals were therefore unlikely to have biased the statistical analysis. All Before the pollen season there were no significant differences between the actively treated and placebo groups for symptoms recorded in diaries, drug scores, conjunctival tests, or the size of the immediate and late skin respones to allergen provocation. For both groups the appearance of symptoms and requirement for drugs followed the increase in the average weekly grass pollen count (fig 1) . Symptom scores peaked on 12 June, one week before the peak in drug scores, which coincided with the peak pollen count (19 June). (18, 12) , 3July (13, 14) , 17_July (14, 16) , 31July (15, 10), 14 August (12, 9) symptoms (p=0.02, 49 v 143 (38 to 111)), blocked nose (p=003, 12 v 44 (3 to 42)), runny nose (p=0 03, 11 v 43 (5 to 43)), total eye symptoms (p=0-02, 37 v 87 (10 to 82)), and streaming eyes (p=002, 0 v 5 (0 to 9)) when Alutard SQ was compared with placebo. Itching eyes, chest symptoms, and mouth and throat symptoms were also reduced, but these differences were of only borderline significance. Drug use was significantly reduced in the Alutard SQ group: sodium cromoglycate eye drops (p=0-01, 14 v 128 (32 to 196) ), sodium cromoglycate nasal spray (p=0-01, 78 v 232 (44 to 234)), and acrivastine (p=0 004, 80 v 174 (35 to 178)). The need for oral prednisolone (nine courses in eight patients) and inhaled salbutamol (two patients) was confined to the placebo group.
At the peak of the season visual analogue scores ( fig  2) were lower in the Alutard group. For 19 June (p= 0-02, 2-2 v 5 5 (-4-8 to-0 5)) there was a 60% decrease in scores (Alutard minus placebo group) and on 3 July a 59% decrease (p=0-01, 1-7 v 4 0 (-5 0 to -1)) (Alutard minus placebo).
The changes in conjunctival allergen sensitivity and the immediate and late skin responses are shown in table IV. Differences in favour of the actively treated patients were found for all three measurements. Figure 3 shows the patients' and doctor's assessment after the season for each patient. The results showed improvement (+3 median value in the active group with +1 in the placebo group); the doctor's median score was + 3 and 0 respectively.
SIDE EFFECTS
Tiredness after injections was commonly reported in both groups. Local reactions of less than 8x8 cm occurred in both groups, but in 523 injections, 22 reactions greater than 8x 8 cm occurred in the active group, 10 of which were in one patient. The patients and coordinator were not told of their meaning or of any adjustments in dose to ensure blinding of the study. The local reactions were not troublesome, and no treatment was required. Four systemic reactions occurred (two in the active and two in the placebo group) during the induction phase of treatment. One reaction was immediate (within 10 minutes) and three delayed (after two hours). This immediate anaphylactic reaction consisted of flushing and chest tightness and responded rapidly to intramuscular adrenaline. The three dlayed reactions consisted of one case of urticaria at 2½12 hours in an actively treated patient, and two episodes of shortness of breath and dizziness at four hours in a placebo treated patient, which were presumed secondary to hyperventilation.
Discussion
In this placebo controlled study immunotherapy with an extract of Phleum pratense was effective in reducing symptoms and requirements for drugs in selected patients with severe hay fever. Clinical improvement was accompanied by decreased target organ (conjunctival) and skin sensitivity.
The high sensitivity of the patients as a group was evident by appreciable symptoms even when the average pollen count was low (7 
